Discover investment opportunities in Best Medical Stocks Under $10 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Medical Stocks Under $10 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Medical Stocks Under $10 using our Smart AI Filter.
8 stocks found for "Best Medical Stocks Under $10"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.92 | ±100.0% | -0.1 | 0.00% | |||
1.01 | ±62.0% | 25.4 | 0.00% | |||
2.07 | ±100.0% | -4.2 | 0.00% | |||
1.66 | ±100.0% | -2.7 | 0.00% | |||
0.35 | ±58.6% | 5.7 | 0.00% | |||
0.70 | ±100.0% | 11.6 | 0.00% | |||
0.77 | ±68.2% | -1.5 | 0.00% | |||
0.86 | ±55.0% | 41.8 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What is the investment appeal of Inovio Pharmaceuticals (INO)?
A: Inovio Pharmaceuticals is appealing to some investors due to its focus on DNA-based vaccines and immunotherapies. The company is working on innovative treatments for infectious diseases, which may have long-term growth potential. However, its volatility and speculative nature should be considered thoroughly.
Q: Does Mallinckrodt (MNK) offer a strong dividend yield?
A: Currently, Mallinckrodt does not offer a dividend yield, making it less attractive for dividend-focused investors. Its focus on specialty pharmaceuticals makes it relevant for those interested in potential turnaround opportunities.
Q: What sector-specific risks are associated with Corbus Pharmaceuticals (CRBP)?
A: Corbus Pharmaceuticals faces sector-specific risks such as regulatory approval processes and competition in rare disease drug development. Their pipeline's success heavily impacts future revenue.
Q: How does Trevena (TRVN) perform in different economic cycles?
A: Trevena, a biopharmaceutical company, can be sensitive to economic cycles due to its reliance on the approval of new drugs. During recessions, funding for biopharmaceutical ventures may be tighter, potentially impacting development timelines.
Q: Is Vaxart (VXRT) considered a growth stock?
A: Some investors consider Vaxart a growth stock due to its quest to develop oral vaccines, potentially revolutionizing vaccine administration. However, its speculative nature and reliance on clinical trial success warrant careful evaluation.
Q: What makes T2 Biosystems (TTOO) strategically appealing?
A: T2 Biosystems is strategically appealing to some investors due to its focus on rapid diagnostic testing. This sector is crucial for improving patient outcomes and reducing healthcare costs, but competition and regulatory hurdles are notable challenges.
Senseonics (SENS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreAytu BioPharma Inc. (AYTU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreThe heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read more